PATENT CLAIM ANALYSIS

Application Number: 15967452
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-04
Patent Classification: ["514", "254070"]

Abstract:
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

Claim (Index 23):
The method of  claim 14 , wherein apalutamide is not co-administered with:\n (a) medications that are primarily metabolized by CYP3A4, preferably darunavir, felodipine, midazolam or simvastatin; (b) medications that are primarily metabolized by CYP2C19, preferably diazepam or omeprazole; (c) medications that are primarily metabolized by CYP2C9, preferably warfarin or phenytoin; or (d) medications that are substrates of UGT, preferably levothyroxine or valproic acid.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.42424
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15967442', '15851444', '14523333', '15222734', '14380606']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.763054337278479
- 35 USC 102 Novelty (BERT): 0.5401180394510899
- Combined Prediction Score: 0.7407607074957401
- Mean Citation Score: 336.3110680000001
- Max Citation Score: 358.95117
- Similarity Product: 230.4109710357696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test